| Literature DB >> 25226279 |
William C Hsu1, Ka Hei Karen Lau1, Motonobu Matsumoto2, Dalia Moghazy1, Hillary Keenan3, George L King4.
Abstract
UNLABELLED: The prevalence of diabetes is rising dramatically among Asians, with increased consumption of the typical Western diet as one possible cause. We explored the metabolic responses in East Asian Americans (AA) and Caucasian Americans (CA) when transitioning from a traditional Asian diet (TAD) to a typical Western diet (TWD), which has not been reported before. This 16-week randomized control pilot feasibility study, included 28AA and 22CA who were at risk of developing type 2 diabetes. Eight weeks of TAD were provided to all participants, followed by 8 weeks of isoenergy TWD (intervention) or TAD (control). Anthropometric measures, lipid profile, insulin resistance and inflammatory markers were assessed. While on TAD, both AA and CA improved in insulin AUC (-960.2 µU/mL × h, P = 0.001) and reduced in weight (-1.6 kg; P<0.001), body fat (-1.7%, P<0.001) and trunk fat (-2.2%, P<0.001). Comparing changes from TAD to TWD, AA had a smaller weight gain (-1.8 to 0.3 kg, P<0.001) than CA (-1.4 to 0.9 kg, P = 0.001), but a greater increase in insulin AUC (AA: -1402.4 to 606.2 µU/mL × h, P = 0.015 vs CA: -466.0 to 223.5 µU/mL × h, P = 0.034) and homeostatic static model assessment-insulin resistance (HOMA-IR) (AA: -0.3 to 0.2, P = 0.042 vs CA: -0.1 to 0.0, P = 0.221). Despite efforts to maintain isoenergy state and consumption of similar energy, TAD induced weight loss and improved insulin sensitivity in both groups, while TWD worsened the metabolic profile. TRIAL REGISTRATION: ClinicalTrials.gov NCT00379548.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25226279 PMCID: PMC4167335 DOI: 10.1371/journal.pone.0106851
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow of participants throughout the study.
aAA, Asian Americans; CA, Caucasian Americans.
Baseline Profile for all participants enrolled Asian Americans vs Caucasian Americans (N = 50).
| Asian Americans (n = 28) | Caucasian Americans (n = 22) | P-value | |
|
| 34.9±8.7 | 33.7±8.2 | 0.550 |
|
| |||
|
| 7 (14.0% of all participants) | 9 (18.0% of all participants) | |
|
| 21 (42.0% of all participants) | 13 (26.0% of all participants) | |
|
| 3 (10.7% of all AA) | 0 (0% of all CA) | |
|
| 6 (21.4% of all AA) | 3 (13.6% of all CA) | |
|
| 163.1±9.7 | 171.1±7.7 | 0.004 |
|
| 61.2±11.5 | 69.6±9.5 | 0.010 |
|
| 22.9±2.8 | 23.7±2.3 | 0.241 |
|
| 5.4±1.1 | 5.4±0.3 | 0.179 |
|
| 26.5±5.3 | 27.5±7.5 | 0.632 |
|
| 25.7±6.4 | 25.2±7.4 | 0.799 |
|
| 0.9±0.1 | 0.9±0.1 | 0.660 |
|
| 109.9±11.9 | 112.0±9.7 | 0.595 |
|
| 71.0±9.8 | 69.6±5.8 | 0.979 |
|
| 5758.2±3782.7 | 3557.8±1291.3 | 0.015 |
|
| 15973.0±3526.5 | 13252.9 ± 3438.5 | 0.012 |
|
| 1.4±1.1 | 1.1±0.5 | 0.309 |
|
| 182.9±35.5 | 176.7±40.2 | 0.469 |
|
| 102.1±113.0 | 75.3±64.0 | 0.082 |
|
| 53.7±17.3 | 58.4±16.7 | 0.314 |
|
| 110.6±35.7 | 99.3±27.3 | 0.207 |
|
| 10.4±12.6 | 10.9±10.8 | 0.953 |
|
| 6.3±2.2 | 6.2±3.8 | 0.389 |
|
| 19.8±5.4 | 19.4±9.1 | 0.591 |
|
| 774.9±864.4 | 2601.2±3169.3 | 0.055 |
|
| 9.2±4.9 | 12.4±9.1 | 0.412 |
|
| 14339.9±9830.0 | 19128.2±8340.7 | 0.046 |
|
| 72.8±179.2 | 23.9±14.6 | 0.007 |
|
| 10.4±5.5 | 8.5±4.9 | 0.214 |
|
| 3.3±2.2 | 3.0±1.8 | 0.675 |
|
| 8.5±3.9 | 9.3±3.5 | 0.230 |
|
| 18.5±6.1 | 12.7±7.3 | 0.006 |
|
| 1.9±1.3 | 2.6±2.4 | 0.571 |
BP, blood pressure; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; HOMA-IR, Homeostatic model assessment-insulin resistance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor-1; % B, endothelium-mediated dilation; % N, non-endothelium-mediated dilation; IL, interleukin; TNF-α, tumor necrosis factor-alpha.
Physiological Responses to Different Diets in Intervention Group, including drop-outs (Intent-to-treat) (N = 41).
| TAD | P-value | TWD | P-value | P-value | |
| ΔVisit 3-Visit 2 | ΔVisit 4-Visit 3 | ||||
|
| −1.6±1.5 | <0.001 | 0.5±1.2 | 0.009 | <0.001 |
|
| −0.6±0.6 | <0.001 | 0.2±0.5 | 0.048 | <0.001 |
|
| −1.7±1.6 | <0.001 | 0.9±1.5 | <0.001 | <0.001 |
|
| −2.2±1.9 | <0.001 | 1.1±2.0 | 0.001 | <0.001 |
|
| 0.0±0.0 | 0.801 | 0.0±0.0 | 0.172 | 0.465 |
|
| 1.6±13.2 | 0.557 | −3.2±7.6 | 0.023 | 0.182 |
|
| −0.2±9.1 | 0.716 | 0.1±8.1 | 0.990 | 0.907 |
|
| −960.2±1775.5 | 0.001 | 438.2±1590.4 | 0.208 | 0.001 |
|
| −1014.2±2098.4 | 0.011 | −161.7±2093.2 | 0.611 | 0.110 |
|
| −0.3±0.7 | 0.022 | 0.1±0.6 | 0.339 | 0.018 |
|
| −25.6±23.9 | <0.001 | 20.4±21.1 | <0.001 | <0.001 |
|
| 9.5±48.4 | 0.526 | 13.0±94.8 | 0.674 | 0.852 |
|
| −10.4±9.6 | <0.001 | 8.2±8.8 | <0.001 | <0.001 |
|
| −14.4±18.8 | <0.001 | 8.1± 14.7 | 0.001 | <0.001 |
|
| −1.9±7.7 | 0.067 | 0.0±10.2 | 0.286 | 0.075 |
|
| 1.1±2.9 | 0.028 | −0.5±2.3 | 0.150 | 0.057 |
|
| −1.5±3.6 | 0.009 | 0.9±3.6 | 0.080 | 0.011 |
|
| −270.0±2160.7 | 0.343 | −190.9±1684.9 | 0.427 | 0.533 |
|
| −2.6±4.0 | <0.001 | 2.1±4.7 | 0.001 | <0.001 |
|
| −1748.2±5626.0 | 0.074 | 2877.6±8381.0 | 0.046 | 0.020 |
|
| −8.4±23.4 | 0.003 | −3.2±40.3 | 0.020 | 0.002 |
|
| 2.5±6.4 | 0.037 | 4.6±6.3 | <0.001 | 0.339 |
|
| 0.2±1.9 | 0.480 | −0.1±1.8 | 0.772 | 0.623 |
|
| 0.1±5.5 | 0.851 | 0.0±4.2 | 0.900 | 0.796 |
|
| 1.0±7.0 | 0.688 | −1.7±5.6 | 0.112 | 0.304 |
|
| −0.2±1.6 | 0.765 | 0.8±1.7 | 0.002 | 0.048 |
BP, blood pressure; CRP, C-reactive protein; HOMA-IR, Homeostatic model assessment-insulin resistance; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor-1; % B, endothelium-mediated dilation; % N, non-endothelium-mediated dilation; IL, interleukin; TAD, traditional Asian diet; TNF-α, tumor necrosis factor-alpha; TWD, typical Western diet.
P-value of the changes observed before and after 8 weeks of TAD (Visit 3-Visit 2).
P-value of the changes observed before and after 8 weeks of TWD (Visit 4-Visit 3).
P-value of the Visit 4-Visit 3 and Visit 3-Visit 2.
Physiological Responses to Different Diets among Asian Americans and Caucasian Americans in Intervention Group, including drop-outs (Intent-to-treat).
| Asian Americans (N = 23) | Caucasian Americans (N = 18) | |||||||||
| TAD | P-value | TWD | P-value | P-value | TAD | P-value | TWD | P-value | P-value | |
| ΔVisit 3-Visit 2 | ΔVisit 4-Visit 3 | ΔVisit 3-Visit 2 | ΔVisit 4-Visit 3 | |||||||
|
| −1.8±1.6 | <0.001 | 0.3±0.9 | 0.131 | <0.001 | −1.4±1.4 | 0.003 | 0.9±1.5 | 0.028 | 0.001 |
|
| −0.6±0.6 | <0.001 | 0.1±0.3 | 0.283 | <0.001 | −0.5±0.5 | 0.001 | 0.3±0.6 | 0.058 | 0.002 |
|
| −1.5±1.6 | <0.001 | 0.7±1.2 | 0.016 | <0.001 | −1.9±1.5 | 0.001 | 1.2±1.7 | 0.017 | 0.001 |
|
| −2.1±2.0 | <0.001 | 0.9±1.8 | 0.019 | 0.001 | −2.4±1.8 | 0.001 | 1.4±2.1 | 0.016 | 0.001 |
|
| 0.0±0.0 | 0.295 | 0.0±0.0 | 0.795 | 0.562 | 0.0±0.0 | 0.056 | 0.0±0.0 | 0.073 | 0.052 |
|
| 1.1±15.2 | 0.831 | −3.2±8.2 | 0.112 | 0.472 | 2.3±10.1 | 0.527 | −3.3±6.9 | 0.098 | 0.184 |
|
| 0.3±10.5 | 0.936 | −1.1±9.7 | 0.602 | 0.667 | −0.9±6.8 | 0.528 | 1.9±5.1 | 0.235 | 0.344 |
|
| −1402.4±2320.8 | 0.017 | 606.2±1898.9 | 0.232 | 0.015 | −466.0±587.1 | 0.008 | 223.5±1094.4 | 0.650 | 0.034 |
|
| −1361.1±2397.9 | 0.025 | −109.6±2476.5 | 0.896 | 0.149 | −626.5±1691.4 | 0.255 | −228.3±1537.5 | 0.463 | 0.433 |
|
| −0.3±0.8 | 0.099 | 0.2±0.7 | 0.232 | 0.042 | −0.1±0.3 | 0.101 | 0.0±0.3 | 0.753 | 0.221 |
|
| −23.9±23.7 | 0.001 | 17.9±20.5 | 0.001 | 0.001 | −27.6±24.8 | 0.001 | 23.3±22.1 | 0.002 | 0.001 |
|
| 15.2±62.7 | 0.526 | 27.9±126.3 | 0.778 | 0.765 | 2.4±20.5 | 0.600 | −5.3±17.3 | 0.249 | 0.289 |
|
| −9.5±9.4 | 0.001 | 6.2±7.1 | 0.002 | <0.001 | −11.6±9.9 | 0.001 | 10.8±10.2 | 0.002 | 0.001 |
|
| −14.0±21.3 | 0.005 | 5.8±14.8 | 0.054 | 0.014 | −14.9±15.6 | 0.003 | 11.1±14.4 | 0.009 | 0.001 |
|
| −1.7±7.9 | 0.313 | −1.4±11.6 | 0.332 | 0.170 | −2.1±7.7 | 0.136 | 1.7±8.2 | 0.583 | 0.239 |
|
| 0.8±2.9 | 0.192 | −0.8±2.5 | 0.117 | 0.154 | 1.4±2.9 | 0.046 | −0.2±1.9 | 0.650 | 0.196 |
|
| −1.5±4.1 | 0.079 | 0.7±3.7 | 0.351 | 0.131 | −1.5±2.9 | 0.055 | 1.4±3.6 | 0.117 | 0.041 |
|
| −50.7±1075.9 | 0.639 | −74.8±1080.6 | 0.627 | 0.741 | −566.8±3102.5 | 0.345 | −348.1±2295.3 | 0.552 | 0.552 |
|
| −2.2±3.7 | 0.014 | 1.6±3.3 | 0.016 | 0.012 | −3.3±4.3 | 0.006 | 2.8±6.1 | 0.023 | 0.002 |
|
| −1071.8±5947.3 | 0.520 | 1344.7±7465.1 | 0.370 | 0.205 | −2612.4±5224.1 | 0.046 | 4836.4±9269.1 | 0.033 | 0.033 |
|
| −13.4±30.4 | 0.012 | −8.7±53.0 | 0.218 | 0.027 | −2.0±4.9 | 0.173 | 3.8±8.9 | 0.028 | 0.033 |
|
| 2.4±7.6 | 0.205 | 6.1±6.8 | 0.002 | 0.192 | 2.7±4.2 | 0.041 | 2.2±4.6 | 0.050 | 0.814 |
|
| 0.3±2.2 | 0.394 | 0.0±1.8 | 1.000 | 0.639 | 0.0±1.4 | 1.000 | −0.2±1.9 | 0.695 | 0.875 |
|
| −0.2±5.8 | 0.689 | 0.1±4.3 | 0.664 | 0.357 | 0.6±5.1 | 0.433 | −0.1±4.4 | 0.754 | 0.530 |
|
| −0.3±7.0 | 0.556 | −2.9±4.8 | 0.030 | 0.455 | 3.1±6.6 | 0.158 | 0.5±6.4 | 1.000 | 0.433 |
|
| 0.1±1.8 | 0.664 | 0.9±1.7 | 0.014 | 0.590 | −0.6±1.4 | 0.196 | 0.8±1.8 | 0.055 | 0.009 |
BP, blood pressure; CRP, C-reactive protein; HOMA-IR, Homeostatic model assessment-insulin resistance; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor-1; % B, endothelium-mediated dilation; % N, non-endothelium-mediated dilation; IL, interleukin; TAD, traditional Asian diet; TNF-α, tumor necrosis factor-alpha; TWD, typical Western diet.
P-value of the changes observed before and after 8 weeks of TAD (Visit 3-Visit 2).
P-value of the changes observed before and after 8 weeks of TWD (Visit 4-Visit 3).
P-value of the Visit 4-Visit 3 and Visit 3-Visit 2.